Food Effect, Efficacy and Safety of MKP10241 in Healthy and Obese Adult Participants, With and Without Diabetes

Base case leans slightly YES because this is an early-phase, placebo-controlled, dose-escalation program centered on PK/PD, food effect, and safety/tolerability rather than a hard clinical efficacy endpoint. Those objectives are usually easier to turn into a favorable readout: even a measurable food effect or supportive PK/PD signal can be considered positive if exposure is interpretable and adverse events are acceptable. The design is sensible for de-risking, with healthy participants for the food-effect portion and obese participants with and without T2DM for multiple-dose characterization, plus Safety Monitoring Committee oversight during escalation. Offsetting that, the study is split across three parts and mixed populations, which can make interpretation less clean. The title references efficacy, but the listed primary endpoints are PK-focused, so eventual positivity may depend heavily on sponsor framing rather than a clear clinical win. The biggest caution is operational: the estimated primary completion date has passed while the study is still listed as recruiting, increasing delay, execution, and disclosure risk. Overall this supports only a modest YES edge.

MKP10241 targets GPR119, a receptor with an exceptionally poor clinical track record. Multiple prior GPR119 agonists (GSK1292263, MBX-2982, DS-8500a, APD668, BMS-903452) have all failed in Phase I/II due to modest glycemic effects and tachyphylaxis, with none advancing past Phase II. Literature reviews from 2024 explicitly note that preclinical rodent success consistently failed to translate clinically. While Part 1 (food-effect PK) will likely generate data, Parts 2-3 (MAD in obese +/- T2DM) test the critical PD/efficacy signal where GPR119 agonists historically collapse. The trial is 73 days past its estimated primary completion yet still shows 'Recruiting' status, suggesting operational delays. Phase 1 safety was acceptable, and preclinical DIO mouse data showed weight and glucose reductions, but prior GPR119 programs showed identical preclinical promise before clinical failure. Mankind Pharma has limited global clinical development experience. Thymus toxicity was flagged by CDSCO as a monitoring concern. The target-class failure rate overwhelmingly dominates the probability assessment.

This Phase 2 trial evaluates MKP10241 PK/PD in obese T2DM patients. The primary endpoints focus on food effect (Cmax, CL/F) - PK parameters rather than clinical efficacy endpoints like HbA1c or weight loss. While the trial includes multiple ascending doses in the target population (obese with/without T2DM), the endpoints are primarily about characterizing pharmacokinetic profile and safety rather than demonstrating clear efficacy. Phase 2 trials have moderate success rates (~30-40% for efficacy endpoints), but this trial's PK-focused endpoints may be more about establishing dose selection for Phase 3 rather than showing definitive efficacy. The trial is past primary completion date (-73 days) and still recruiting, suggesting possible enrollment challenges. Overall, I estimate ~55% intrinsic YES probability given the PK-focused endpoints and Phase 2 positioning, though the

The trial is a Phase 2 study focused on food effect, safety, and PK/PD of MKP10241 in obese participants with and without T2DM. The primary endpoints are standard pharmacokinetic measures (Cmax, CL/F) for Part 1, which are objective and likely to be met for a well-characterized molecule in a food-effect assessment. The study design is straightforward, comparing fasting and fed states. The sponsor, Mankind Pharma, has operational experience. The main risks are from the later multiple-ascending-dose parts (Parts 2 & 3) which assess safety and pharmacodynamics in a more complex population; however, the trial question 'Will the results be positive?' is broad and likely refers to the overall study success on these exploratory endpoints. Given the early phase nature and focus on characterization rather than stringent efficacy, the probability leans slightly positive.

This Phase 2 trial assesses food effect (primary), PK/PD profile, safety/tolerability of MKP10241 via three parts: Part 1 single-dose PK (Cmax, CL/F fed vs fasted), Parts 2-3 multiple ascending doses (200-400mg x28 days) in obese ±T2DM vs placebo. Primary endpoints are gold-standard PK measures, objective and high-quality, with success defined as characterizing acceptable food effect (typically bioequivalence within 80-125% limits), rarely failing (<10% historical rate for such studies). Patient population (healthy, obese, T2DM adults) aligns perfectly with indication, enabling robust PK/PD signals. No prior data, but early Phase 2 PK/safety focus yields ~80% success baseline. Design includes dose escalation, SMC oversight, placebo control for clean assessment. Operational risks minor: recruiting despite -73 day primary delay suggests execution hiccups but no toxicity/futility halt. Disclosure risk low; PK results straightforward, positive if no major food impact or AEs.

This Phase 2 trial for MKP10241 targets T2DM and obesity, indications with well-established regulatory pathways. The multi-part design (food effect, multiple ascending doses) allows for robust data collection across healthy and obese populations with and without diabetes. The inclusion of a Safety Monitoring Committee indicates proactive risk management. While the primary endpoints focus on pharmacokinetics (Cmax, CL/F) under fed/fasting conditions, these are standard bioequivalence metrics unlikely to fail for an oral small molecule unless formulation is poor. Sponsor Mankind Pharma has established generic development expertise, de-risking operational execution. The 28-day dosing regimen in Parts 2 and 3 should provide sufficient safety and preliminary efficacy signals (pharmacodynamics). However, the novel mechanism lacks disclosed preclinical or Phase 1 data, introducing uncertainty regarding efficacy. Primary completion was estimated Jan 2026; current 'Recruiting' status suggests delays. Overall, PK endpoints and safety focus tilt probability slightly positive, but efficacy uncertainty tempers confidence.

Phase 2 food effect/PK study for MKP10241, a GLP-1 agonist candidate. Trial completed 73 days ago (primary completion Jan 19, 2026), now in recruiting status suggesting database lock or analysis phase. Design is standard: 3 parts covering food effect, multiple ascending doses in obese with/without T2DM, with placebo control and Safety Monitoring Committee oversight. Primary endpoints are pharmacokinetic (Cmax, CL/F) rather than clinical efficacy—PK parameters are objective, measurable, and typically achievable for small molecules. Sponsor Mankind Pharma has commercial manufacturing scale and Indian regulatory experience. Key risks: disclosure timing uncertain (Indian companies have variable transparency), and Part 2/3 multiple-dose safety data in T2DM patients could show liver enzyme elevations or GI intolerance common to GLP-1 class. No prior Phase 1 data disclosed publicly, but progression to Phase 2 implies acceptable Phase 1 safety. Overall, PK studies have high technical success rates (~75%), and the 400mg dose selection suggests prior dose-ranging confidence.

MKP10241 is a GPR119 agonist currently in a Phase 2 trial. The listed primary endpoints are exclusively from Part 1, focusing purely on observational pharmacokinetic parameters (Cmax and apparent total clearance) to determine the food effect of a single dose over 18 days. Unlike efficacy endpoints that require demonstrating statistical superiority against a placebo, observational PK endpoints are virtually guaranteed to be met as long as the trial is safely completed and the drug's plasma concentration is measurable. Given that Mankind Pharma has already successfully completed Phase 1 studies for MKP10241, basic tolerability and systemic absorption are established, heavily de-risking this Part 1 readout. While Parts 2 and 3 of the trial will explore multiple ascending doses and early efficacy signals in obese and T2DM patients, the formal primary endpoints strictly govern the food-effect PK. The historical success rate for early-stage PK and food-effect evaluation trials routinely exceeds 85%. The prediction market's implied probability of roughly 50% severely underestimates the structural likelihood of success for an observational primary endpoint.

The trial is in Phase 2, which is a relatively early stage but still informative. The study involves a significant number of participants, including healthy individuals and those with Type 2 Diabetes Mellitus (T2DM) and obesity, which could provide valuable insights into the drug's efficacy and safety across different populations. The primary endpoint focuses on pharmacokinetic parameters such as Cmax and CL/F under fasting and fed conditions, which are crucial for understanding the drug's behavior in the body. Given that the trial is recruiting and has not yet reached its primary completion date, there is inherent uncertainty. However, the study's design, which includes both healthy participants and those with T2DM and obesity, and its focus on pharmacokinetics and pharmacodynamics, suggest a potentially positive outcome if the drug demonstrates favorable safety and efficacy profiles.